BMI View: The Mozambican health sector has suffered from years of neglect and the damage caused by a
devastatingly long civil war. In recent years, the government has shown its commitment to improving the
country’s healthcare infrastructure and we expect increasing public expenditure, coupled with a high
disease burden, to continue driving the demand for medicines over the long-term. However, we note that
weak intellectual property protection and a poor regulatory environment continue to plague the market.
These issues are unlikely to be sufficiently addressed in the foreseeable future, especially considering the
increasingly tense political climate.
Headline Expenditure Forecasts
? Pharmaceuticals: MZN8.28bn (USD210mn) in 2015 to MZN9.02bn (USD184mn) in 2016; +8.9% in
local currency and -12.3% in US dollar terms. Forecast in line with last quarter.
? Healthcare: MZN38.89bn (USD985mn) in 2015 to MZN43.15bn (USD881mn) in 2016; +10.9% in local
currency and -10.6% in US dollar terms. Forecast in line with last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Mozambique 2014-2020) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2012-2020) 12
Healthcare Market Forecast 12
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020) 15
Industry Risk Reward Index 16
Middle East and Africa Risk/Reward Index - Q2 2016 16
Mozambique Risk/Reward Index 23
Rewards 23
Risks 23
Regulatory Review 24
Regulatory Development 24
Intellectual Property Issues 25
Pricing Regime 25
Market Overview 26
Healthcare Sector 26
Clinical Trials 27
Epidemiology 27
Competitive Landscape 30
Research-Based Industry 30
Pharmaceutical Distribution 31
Pharmaceutical Retail Sector 31
Company Profile 32
Sociedade Moçambicana de Medicamentos (SMM) 32
Demographic Forecast 34
Table: Population Headline Indicators (Mozambique 1990-2025) 35
Table: Key Population Ratios (Mozambique 1990-2025) 35
Table: Urban/Rural Population & Life Expectancy (Mozambique 1990-2025) 36
Table: Population By Age Group (Mozambique 1990-2025) 36
Table: Population By Age Group % (Mozambique 1990-2025) 37
Glossary 39
Methodology 41
Pharmaceutical Expenditure Forecast Model 41
Healthcare Expenditure Forecast Model 41
Notes On Methodology 42
Risk/Reward Index Methodology 43
Index Overview 44
Table: Pharmaceutical Risk/Reward Index Indicators 44
Indicator Weightings 45

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Mozambique 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Mozambique 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Mozambique 2012-2020)
Table: Population Headline Indicators (Mozambique 1990-2025)
Table: Key Population Ratios (Mozambique 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Mozambique 1990-2025)
Table: Population By Age Group (Mozambique 1990-2025)
Table: Population By Age Group % (Mozambique 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators